188 related articles for article (PubMed ID: 30239650)
21. Protective effect of CCR5-Δ32 against HIV infection by the heterosexual mode of transmission in a Polish population.
Zwolińska K; Knysz B; Rybka K; Pazgan-Simon M; Gąsiorowski J; Sobczyński M; Gładysz A; Piasecki E
AIDS Res Hum Retroviruses; 2013 Jan; 29(1):54-60. PubMed ID: 22957692
[TBL] [Abstract][Full Text] [Related]
22. Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients.
Neukam K; Mira JA; Ruiz-Morales J; Rivero A; Collado A; Torres-Cornejo A; Merino D; de Los Santos-Gil I; Macías J; González-Serrano M; Camacho A; Parra-García G; Pineda JA;
J Antimicrob Chemother; 2011 Nov; 66(11):2605-14. PubMed ID: 21903660
[TBL] [Abstract][Full Text] [Related]
23. Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis.
Lefebvre E; Moyle G; Reshef R; Richman LP; Thompson M; Hong F; Chou HL; Hashiguchi T; Plato C; Poulin D; Richards T; Yoneyama H; Jenkins H; Wolfgang G; Friedman SL
PLoS One; 2016; 11(6):e0158156. PubMed ID: 27347680
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics, Safety, and CCR2/CCR5 Antagonist Activity of Cenicriviroc in Participants With Mild or Moderate Hepatic Impairment.
Lefebvre E; Gottwald M; Lasseter K; Chang W; Willett M; Smith PF; Somasunderam A; Utay NS
Clin Transl Sci; 2016 Jun; 9(3):139-48. PubMed ID: 27169903
[TBL] [Abstract][Full Text] [Related]
25. Safety, efficacy, and pharmacokinetics of TBR-652, a CCR5/CCR2 antagonist, in HIV-1-infected, treatment-experienced, CCR5 antagonist-naive subjects.
Lalezari J; Gathe J; Brinson C; Thompson M; Cohen C; Dejesus E; Galindez J; Ernst JA; Martin DE; Palleja SM
J Acquir Immune Defic Syndr; 2011 Jun; 57(2):118-25. PubMed ID: 21317794
[TBL] [Abstract][Full Text] [Related]
26. Molecular mechanisms of liver fibrosis in HIV/HCV coinfection.
Mastroianni CM; Lichtner M; Mascia C; Zuccalà P; Vullo V
Int J Mol Sci; 2014 May; 15(6):9184-208. PubMed ID: 24865485
[TBL] [Abstract][Full Text] [Related]
27. IP-10 correlates with hepatitis C viral load, hepatic inflammation and fibrosis and predicts hepatitis C virus relapse or non-response in HIV-HCV coinfection.
Reiberger T; Aberle JH; Kundi M; Kohrgruber N; Rieger A; Gangl A; Holzmann H; Peck-Radosavljevic M
Antivir Ther; 2008; 13(8):969-76. PubMed ID: 19195322
[TBL] [Abstract][Full Text] [Related]
28. Effects of Therapy with Maraviroc on the Carotid Intima Media Thickness in HIV-1/HCV Co-infected Patients.
Maggi P; Bruno G; Perilli F; Saracino A; Volpe A; Santoro C; Ladisa N; Angarano G
In Vivo; 2017 Jan; 31(1):125-131. PubMed ID: 28064231
[TBL] [Abstract][Full Text] [Related]
29. Delayed liver fibrosis in HTLV-2-infected patients co-infected with HIV-1 and hepatitis C virus with suppressive antiretroviral therapy.
Abad-Fernández M; Moreno A; Dronda F; del Campo S; Quereda C; Casado JL; Pérez-Elías MJ; Moreno S; Vallejo A
AIDS; 2015 Feb; 29(4):401-9. PubMed ID: 25565497
[TBL] [Abstract][Full Text] [Related]
30. HIV infection does not increase the risk of liver complications in hepatitis C virus-infected patient with advanced fibrosis, after sustained virological response with direct-acting antivirals.
Corma-Gómez A; Morano L; Téllez F; Rivero-Juárez A; Real LM; Alados JC; Ríos-Villegas MJ; Vera-Méndez FJ; Muñoz RP; Geijo P; Macías J; Pineda JA;
AIDS; 2019 Jun; 33(7):1167-1174. PubMed ID: 30845068
[TBL] [Abstract][Full Text] [Related]
31. Incompatible Natures of the HIV-1 Envelope in Resistance to the CCR5 Antagonist Cenicriviroc and to Neutralizing Antibodies.
Kuwata T; Enomoto I; Baba M; Matsushita S
Antimicrob Agents Chemother; 2016 Jan; 60(1):437-50. PubMed ID: 26525792
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis.
Krenkel O; Puengel T; Govaere O; Abdallah AT; Mossanen JC; Kohlhepp M; Liepelt A; Lefebvre E; Luedde T; Hellerbrand C; Weiskirchen R; Longerich T; Costa IG; Anstee QM; Trautwein C; Tacke F
Hepatology; 2018 Apr; 67(4):1270-1283. PubMed ID: 28940700
[TBL] [Abstract][Full Text] [Related]
33. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection.
Aranzabal L; Casado JL; Moya J; Quereda C; Diz S; Moreno A; Moreno L; Antela A; Perez-Elias MJ; Dronda F; Marín A; Hernandez-Ranz F; Moreno A; Moreno S
Clin Infect Dis; 2005 Feb; 40(4):588-93. PubMed ID: 15712082
[TBL] [Abstract][Full Text] [Related]
34. HIV and hepatitis C coinfection: pathogenesis and microbial translocation.
Page EE; Nelson M; Kelleher P
Curr Opin HIV AIDS; 2011 Nov; 6(6):472-7. PubMed ID: 21918438
[TBL] [Abstract][Full Text] [Related]
35. Frequency of the CCR5 delta 32 mutant allele in HIV-1-positive patients, female sex workers, and a normal population in Taiwan.
Li C; Yan YP; Shieh B; Lee CM; Lin RY; Chen YM
J Formos Med Assoc; 1997 Dec; 96(12):979-84. PubMed ID: 9444918
[TBL] [Abstract][Full Text] [Related]
36. A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis.
Friedman SL; Ratziu V; Harrison SA; Abdelmalek MF; Aithal GP; Caballeria J; Francque S; Farrell G; Kowdley KV; Craxi A; Simon K; Fischer L; Melchor-Khan L; Vest J; Wiens BL; Vig P; Seyedkazemi S; Goodman Z; Wong VW; Loomba R; Tacke F; Sanyal A; Lefebvre E
Hepatology; 2018 May; 67(5):1754-1767. PubMed ID: 28833331
[TBL] [Abstract][Full Text] [Related]
37. Cenicriviroc for the treatment of non-alcoholic steatohepatitis and liver fibrosis.
Tacke F
Expert Opin Investig Drugs; 2018 Mar; 27(3):301-311. PubMed ID: 29448843
[TBL] [Abstract][Full Text] [Related]
38. Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C.
Promrat K; McDermott DH; Gonzalez CM; Kleiner DE; Koziol DE; Lessie M; Merrell M; Soza A; Heller T; Ghany M; Park Y; Alter HJ; Hoofnagle JH; Murphy PM; Liang TJ
Gastroenterology; 2003 Feb; 124(2):352-60. PubMed ID: 12557141
[TBL] [Abstract][Full Text] [Related]
39. Comparison of the beneficial effects of RS504393, maraviroc and cenicriviroc on neuropathic pain-related symptoms in rodents: behavioral and biochemical analyses.
Kwiatkowski K; Ciapała K; Rojewska E; Makuch W; Mika J
Int Immunopharmacol; 2020 Jul; 84():106540. PubMed ID: 32402949
[TBL] [Abstract][Full Text] [Related]
40. Better CD4+ T cell recovery in Brazilian HIV-infected individuals under HAART due to cumulative carriage of SDF-1-3'A, CCR2-V64I, CCR5-D32 and CCR5-promoter 59029A/G polymorphisms.
Rigato PO; Hong MA; Casseb J; Ueda M; de Castro I; Benard G; Duarte AJ
Curr HIV Res; 2008 Sep; 6(5):466-73. PubMed ID: 18855658
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
